![]()
- Consumer Mood Improves, But Anxiety Over Finances
- Jobless Claims Below 500,000, Durable Orders Slip
- Garlic Price Rises Surpass Gold, Stocks in China
- Judge Erases Couple's $525,000 Mortgage Payment
- Obama Going to Copenhagen Climate Summit
- Half of Banks' Losses May Still Be Hidden: IMF Head
- Seeking Deals, Holiday Fliers Get Early Start
- Americans Ditch Planes for Trains this Thanksgiving
- FDIC's Bair Cautions on Risks in Bank Break-Up Plan
- Art Cashin: Caution 'Growing' in Financials, Dividend Moves
- Topless Business Is Taking Off
- 3 Software Stock Picks from Lazard's Senior Analyst
- Schork Oil Outlook: Gas Bulls Pinning Hopes on Mother Nature
- Toyota Makes Recall Fix And So Long Saab
- Investors Bet on a New Year's Rally For eBay
- Why You Should Play the Reflation Trade: Stock Picker
- Citi Mortgage Reveals What Treasury Won't
- S&P to Hit 1,200 by Year-End: Chief Investor
MOST SHARED
- Ritz-Carlton ?Struggling? in the US: President
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Garlic Price Rises Surpass Gold, Stocks in China
- Oil Price to Average $75.40 in 2010: Poll
- Obama Reiterates Commitment to Boost US-India Ties
- Half of Banks' Losses May Still Be Hidden: IMF Head
- New-Home Sales Jump 6.2% To Highest Level in Over Year
- Jobless Claims Below 500,000, Durable Orders Slip
- Americans Ditch Planes for Trains this Thanksgiving
Biogen Idec, which has put itself up for sale, may get bids of around $25-30 billion from several of the world's top drugmakers keen to expand in the hot area of biotech medicine.
Pfizer, Sanofi-Aventis and Johnson & Johnson [JNJ
Loading...
()
] could all use the U.S. company to gain scale in protein and antibody drug manufacturing, sales and research, bankers and industry analysts said on Monday.
Roche Holding, however, may be less interested - despite its collaboration with Biogen on cancer drug MabThera/Rituxan - since it already has a major presence in biotech medicine production.
GlaxoSmithKline, another player with a potential appetite, is also probably not in the running, as it focuses on other priorities, some industry experts said.
Roche's Swiss rival Novartis [NVS
Loading...
()
], meanwhile, has a competing presence in multiple sclerosis which could rule it out from buying Biogen.
Officials at all the firms declined to comment.
"A number of big companies have said recently they don't think they are big enough in biotech yet, so I would think there will be quite a lot of interest," said Paul Diggle of Nomura Code Securities.
Acquiring Biogen [BIIB
Loading...
()
] will not be cheap, however.
The unexpectedly rich price of $15.6 billion paid for U.S. biotech firm MedImmune by AstraZeneca earlier this year - equivalent to 11-times annual sales - showed big pharma's appetite for biotech assets.
That same high valuation would value Biogen at about $34 billion.
In practice, analysts believe threats to Biogen's core multiple sclerosis franchise from new products and the risk of biogeneric competition to its established MS drug Avonex in the years ahead mean a lowlier rating is justified.
New MS Drug Tysabri a Wild Card
On the plus side, new MS drug Tysabri is now seen by some analysts as a potential multibillion-dollar-year seller. Biogen collaborates on the drug with Elan [ELN
Loading...
()
].
"The key variable in the take-out price is the outlook for Tysabri," said Geoffrey Porges, an analyst at Sanford Bernstein, who estimates Biogen will fetch between $85 to $100 a share.
Investors are clearly anticipating a keen tussle, with Biogen shares rising 19 percent in Nasdaq trade on Monday to $82.50, valuing the business at around $23 billion.
The prize offered Biogen is a bridgehead into the biological medicines market, where growth is faster and margins higher than in traditional pharmaceuticals.
"A lot of people want biological capacity. Those who have it already probably won't be bidders, so I guess you can probably count out Roche and AstraZeneca," said Ben Yeoh, an industry analyst at Dresdner Kleinwort.
France's Sanofi-Aventis [SNY
Loading...
()
], the world's third-largest drugmaker, said last month it was looking for acquisitions in biotechnology - particularly in manufacturing.
Pfizer [PFE
Loading...
()
], the global number one in pharmaceuticals, has also trumpeted its determination to be a leader in biotech.
"Sanofi is looking for more biological products and Pfizer is doing the same," said Tim Race of brokerage ING.
Biogen's announcement late on Friday comes four years after Biogen was acquired by Idec Pharmaceutical for $6.7 billion.
The company said it hired Goldman Sachs [GS
Loading...
()
] and Merrill Lynch [MER
Loading...
()
] to help find a buyer and that it has already received "expressions of interest."
One interested party is billionaire investor Carl Icahn, who recently took control of ImClone Systems [IMCL
Loading...
()
] and has increased his stake in Biogen to about 4 percent.
- Here's how key provisions of the health care reform bill would impact your insurance and how you'll pay for it.
- Playboy will outsource its publishing operations in a bid to become profitable again.
- Remember when auto shows were major events where new models could generate buzz?
- After nine years the NBA’s minor league equivalent is finally coming into its own.
- Bill Griffeth is taking a leave of absence from CNBC and Power Lunch for a year. Here's a message from Bill.
- For nearly three decades, these on-call experts have been dishing advice on how to – and not to – cook turkey.












